Physician profile
Mark A Rubin
NPI 1255354163
$473.93
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.67 · 2020: $84.67 · 2021: $46.63 · 2023: $80.27 · 2024: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $133.35 | 2024 | Tremfya |
| Abbvie INC. | $87.60 | 2019-2021 | |
| Amgen INC. | $68.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.17 | 2023-2024 | Ninlaro |
| Ucb, INC. | $28.51 | 2024 | Bimzelx |
| Leo Pharma INC. | $23.83 | 2019 | |
| Medtronic USA, INC. | $21.86 | 2019 | |
| Biofrontera INC. | $19.94 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genmab U.S., INC. | $16.98 | 2023 | Epkinly |
| Morphosys, US INC. | $16.01 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.